Generic Reductil(Meridia) - Best Solution to Figt Obesity

Reductil (known as Meridia in the USA) is an Weight loss treatment for obese patients with a BMI above 30. It is a prescription only weight loss drug and works to control the appetite within the brain. This slimming medication has shown positive results in patients worldwide and in clinical trials especially when combined with a balanced and healthy diet along with regular exercise. Studies have shown that using Meridia, along with a reduced caloric diet and exercise, helped patients lose weight and maintain weight loss for up to two years. Reductil (Meridia) usually helps people to lose an average of around 10 per cent of their starting body weight and for up to two years after can help patients to maintain their new weight.

Reductil, which contains sibutramine is a medicine to help you lose weight if your doctor has determined you are obese, or overweight with additional risk factors for obesity such as diabetes and/or elevated lipids. Your doctor may start you on Reductil if diet and exercise for three months didn’t help you lose enough weight. This medicine makes you feel full sooner so you eat less food. By eating less you should be able to lose and control your weight. This medicine is part of your weight loss plan you set up with your doctor.

This medicine should be used together with a low calorie diet and an increase in your physical activity. The combination will also help you lose weight. Your doctor will guide you with your weight loss program and will give you regular check-ups.

Studies have shown that Meridia is moderately effective in producing weight loss in obese individuals, with 85 percent losing at least 5 percent of body weight and 57 percent at least 10 percent. In the majority of studies it has not been shown to be as effective as the combination of fenfluramine and phentermine which enhances the release of norepinephrine and serotonin. Subjects in studies by Weintraub and Wadden lost an average of 15.9 percent of body weight. However, with the withdrawal of fenfluramine from the market in 1997, the combination is no longer available.

Animals given sibutramine have shown an increase in metabolic rate, but human studies have not been conclusive. The reasons for the difference between animals and humans is not clear but may be due to the small number of subjects tested and the small effect of the drug on energy expenditure. However, even small increases in thermogenesis could be clinically significant in weight loss and weight maintenance.